Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,078 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Male Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

NCT02998775
View directory record Official record
Conditions
Hepatic Impairment; Renal Impairment
Interventions
Plasma Sampling
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)

NCT06665230
View directory record Official record
Conditions
Healthy, Narcolepsy
Interventions
MK-6552, Modafinil
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration

NCT06278766
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

GSK706769 A First Time in Human Study For Males and Females

NCT00539201
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK706769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Finasteride Tablets 5 mg and Proscar® Tablets 5 mg

NCT00650377
View directory record Official record
Conditions
Healthy
Interventions
Finasteride Tablets 5 mg, Proscar® Tablets 5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of a Couple-Focused mHealth Symptom Self-management Program

NCT03489057
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Cancer Education and Resources for Couples (PERC), usual care plus NCI website
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
40 Years to 75 Years
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 23, 2026, 9:06 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT05650112
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
FB-001, Placebo
Biological
Lead sponsor
Federation Bio Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

NCT00665665
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC 0070-0002-0182, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

NCT02754687
View directory record Official record
Conditions
Healthy Men, Male Contraception
Interventions
Placebo, 11βmethyl nortestosterone dodecylcarbonate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

NCT06738836
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C]-EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

NCT02207790
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

NCT01846520
View directory record Official record
Conditions
Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Psychosocial Effects of Cancer and Its Treatment, Recurrent Bladder Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Uterine Sarcoma, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage II Bladder Cancer, Stage II Renal Cell Cancer, Stage II Urethral Cancer, Stage IIA Cervical Cancer, Stage IIA Colon Cancer, Stage IIA Gastric Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIA Uterine Sarcoma, Stage IIB Cervical Cancer, Stage IIB Colon Cancer, Stage IIB Gastric Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIB Uterine Sarcoma, Stage IIC Colon Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage IIC Rectal Cancer, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage III Urethral Cancer, Stage IIIA Cervical Cancer, Stage IIIA Colon Cancer, Stage IIIA Gastric Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Rectal Cancer, Stage IIIA Uterine Sarcoma, Stage IIIB Cervical Cancer, Stage IIIB Colon Cancer, Stage IIIB Gastric Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Rectal Cancer, Stage IIIB Uterine Sarcoma, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Rectal Cancer, Stage IIIC Uterine Sarcoma, Stage IV Bladder Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IV Urethral Cancer, Stage IVA Cervical Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Uterine Sarcoma, Stage IVB Cervical Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Stage IVB Uterine Sarcoma, Ureter Cancer, Stage IIA Lung Carcinoma, Stage IIB Lung Carcinoma, Stage IIIA Lung Carcinoma, Stage IIIB Lung Carcinoma
Interventions
educational intervention, telephone-based intervention, quality-of-life assessment, questionnaire administration
Other · Behavioral · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

NCT03641573
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C] ASN002
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Not applicable Interventional

Healthy Transitions in Late Stage Kidney Disease

NCT02085837
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Education, Daily weight measurement and monitoring, Universal Dietary education, Medication review, Focused advanced directive program, Countdown to fistula program
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

NCT04616027
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Impairment, Healthy
Interventions
PF-06882961 20 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol

NCT01594619
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
Naloxegol, Diltiazem XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil

NCT04039373
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986256, Mycophenolate Mofetil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 Days

NCT00791388
View directory record Official record
Conditions
Healthy
Interventions
Placebo, PG-760564
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects

NCT04621318
View directory record Official record
Conditions
Healthy
Interventions
Denosumab
Drug
Lead sponsor
Samsung Bioepis Co., Ltd.
Industry
Eligibility
28 Years to 55 Years · Male only
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects

NCT02059590
View directory record Official record
Conditions
Pharmacokinetics of 14C-labeled Isavuconazonium Sulfate, Healthy Subjects
Interventions
Pyridinylmethyl-14C-labeled isavuconazonium sulfate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 23, 2026, 9:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating a Mat-Based Biometric Vibration System for Sleep and Daily Recovery

NCT07221318
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
Low-frequency whole-body vibration mat
Device
Lead sponsor
Florida International University
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 23, 2026, 9:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCT07144527
View directory record Official record
Conditions
Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions
NMN and TMG (Euexia), Nicotinamide Mononucleotide (NMN), Placebo
Dietary Supplement
Lead sponsor
Scott Silveira
Other
Eligibility
60 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118

NCT01520896
View directory record Official record
Conditions
Bioavailability, Healthy Volunteers, Drug- Drug Interactions
Interventions
NKTR-118, Ketoconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415
View directory record Official record
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions
NKTR-118, moxifloxacin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 23, 2026, 9:06 AM EDT